Introduction
This Modern Slavery and Human Trafficking Statement is a response to Section 54(1), Part 6 of the Modern Slavery Act 2015 and relates to actions and activities for the financial year ending 31 January 2022.
Spark Medical Limited (‘the Company’, ‘we’, ‘us’ or ‘our’) is committed to preventing slavery and human trafficking violations in its own operations, its supply chain, and its products. We have zero-tolerance towards slavery and require our supply chain to comply with our values.
Organisational structure
Spark Medical Limited has business operations in the United Kingdom.
We operate in the private medical sector sector. The nature of our supply chains is as follows: We work with a number of NHS trusts and event providers to provide ambulance and event medical cover.
For more information about the Company, please visit our website: SparkMedical.co.uk.
Policies
We operate a number of internal policies to ensure that we are conducting business in an ethical and transparent manner.
These include the following:
· Recruitment and selection policy – By ensuring Spark Medical have a fit and robust recruitment process we will ensure that all staff have the correct documentation, checks and qualifications to provide safe, effective care.
· Whistleblowing policy – Spark Medical’s whistleblowing policy is in place to ensure that all staff can with confidence raise concerns in the workplace with the knowledge that the concern will be fully investigated
· Staff code of conduct – Spark Medical staff adhere to our TEAM values, these values place patient centred care at the heart of everything we do, they ensure we are respectful and treat others with dignity.
· Safeguarding policy – Spark Medical’s Safeguarding policy is in place to ensure that all staff have support and guidance available to them when raising a safeguarding concern, the policy gives clear step by step instructions as well as useful contact details for local authority teams and Spark Medical Safeguarding Leads.
We make sure our suppliers are aware of our policies and adhere to the same standards.
Due Diligence
As part of our efforts to monitor and reduce the risk of slavery and human trafficking occurring in our supply chains, we have adopted the following due diligence procedures:
· External supplier audits.
Our due diligence procedures aim to:
· Identify and action potential risks in our business and supply chains.
· Monitor potential risks in our business and supply chains
· Reduce the risk of slavery and human trafficking occurring in our business and supply chains.
· Provide protection for whistleblowers.
Risk and compliance
The Company has evaluated the nature and extent of its exposure to the risk of slavery and human trafficking occurring in its UK supply chain through:
· Reviewing on a regular basis all aspects of the supply chain based on supply chain mapping.
We do not consider that we operate in a high-risk environment because the majority of our supply chain is based in the UK and in low-risk industries, such as internet software and services.
We do not tolerate slavery and human trafficking in our supply chains. Where there is evidence of failure to comply with our policies and procedures by any of our suppliers, we will require that supplier to remedy the non-compliance.
Effectiveness
The Company uses Key Performance Indicators (KPIs) to measure its effectiveness and ensure that slavery and human trafficking is not taking place in its business and supply chains. These KPIs are as follows:
· We will contact suppliers to enquire about their modern slavery practices every 6 months.
· We will train our staff about modern slavery issues and increase awareness within the Company.
Training our staff
The Company requires its staff to complete training and ongoing refresher courses on slavery and human trafficking. The Company’s training covers:
· How to identify the signs of slavery and human trafficking.
· What initial steps should be taken if slavery or human trafficking is suspected.
· How to escalate potential slavery or human trafficking issues to the relevant parties within the Company.
The statement was approved by the board of directors on the 30th October 2024
